Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet

BMC Chemistry

Table 13 Assay results for the determination of VPS and SFV in their co-formulated tablet by Method 2

Studied drug	Proposed method						Comparison method [11]
	Amount taken (ng/mL)		Amount found (ng/mL)		% Found		% Found
	Column (A)	Column (B)	Column (A)	Column (B)	Column (A)	Column (B)	% Found
SFV Epclusa^® tablet (SFV 400 mg/VPS 100 mg)	200.0	200.0	196.900	199.520	98.45	99.76	99.98
	400.0	400.0	389.760	394.920	97.44	98.73	98.93
	600.0	600.0	596.760	589.080	99.46	98.18	100.83
Mean					98.45	98.89	100.85
±SD					1.01	0.80	0.95
t-test					1.83	1.42	(2.78)*
F-test					1.12	1.41	(19)*
VPS	50.0	50.0	48.810	49.955	97.62	99.91	102.45
Epclusa^® tablet (SFV 400 mg/VPS 100 mg)	100.0	100.0	98.000	98.040	98.00	98.04	101.78
Epclusa^® tablet (SFV 400 mg/VPS 100 mg)	150.0	150.0	148.665	148.185	99.11	98.79	98.91
Mean					98.24	98.91	101.05
±SD					0.77	0.94	1.88
t-test					2.39	1.76	(2.78)*
F-test					5.89	3.99	(19.0)*

Each result is the average of three separate determinations
* The figures between parentheses are the tabulated t and F values at P = 0.05 [17]